Marizyme Stock Probability Of Bankruptcy
| MRZM Stock | USD 0.05 0.01 25.00% |
Marizyme |
Marizyme OTC Stock odds of distress Analysis
Marizyme's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Marizyme Probability Of Bankruptcy | Less than 26% |
Most of Marizyme's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Marizyme is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Marizyme probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Marizyme odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Marizyme financial health.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
| Competition |
Based on the latest financial disclosure, Marizyme has a Probability Of Bankruptcy of 26.0%. This is 39.94% lower than that of the Software sector and 52.59% lower than that of the Information Technology industry. The probability of bankruptcy for all United States stocks is 34.72% higher than that of the company.
Marizyme Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Marizyme's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Marizyme could also be used in its relative valuation, which is a method of valuing Marizyme by comparing valuation metrics of similar companies.Marizyme is currently under evaluation in probability of bankruptcy category among its peers.
Marizyme Fundamentals
| Return On Equity | -0.5 | |||
| Return On Asset | -0.15 | |||
| Operating Margin | (180.85) % | |||
| Current Valuation | 17.35 M | |||
| Shares Outstanding | 10.13 M | |||
| Shares Owned By Insiders | 2.04 % | |||
| Price To Book | 0.37 X | |||
| Price To Sales | 133.06 X | |||
| Revenue | 210.28 K | |||
| Gross Profit | 129.93 K | |||
| EBITDA | (10.83 M) | |||
| Net Income | (11 M) | |||
| Cash And Equivalents | 2.04 M | |||
| Cash Per Share | 0.05 X | |||
| Total Debt | 495.32 K | |||
| Debt To Equity | 0.07 % | |||
| Current Ratio | 1.74 X | |||
| Book Value Per Share | 1.00 X | |||
| Cash Flow From Operations | (5.79 M) | |||
| Earnings Per Share | (0.39) X | |||
| Number Of Employees | 11 | |||
| Beta | 0.36 | |||
| Market Capitalization | 5.07 M | |||
| Total Asset | 66 M | |||
| Z Score | 6.0 | |||
| Net Asset | 66 M |
About Marizyme Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Marizyme's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Marizyme using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Marizyme based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Marizyme OTC Stock
Marizyme financial ratios help investors to determine whether Marizyme OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Marizyme with respect to the benefits of owning Marizyme security.